BUPRENORPHINE BUCCAL FILM: A NOVEL MUCOADHEVISE APPROACH FOR CHRONIC PAIN MANAGEMENT

Priyanka N

doi:10.46956/ijihd.v11i1.817

N. Priyanka Associate Professor, Department of Pharmaceutics, St.Ann’s College of Pharmacy, Chirala.

DOI https://doi.org/10.46956/ijihd.v11i1.817

Abstract

Chronic pain remains a significant clinical challenge requiring long-term, effective, and safe therapeutic strategies. Buprenorphine buccal film has emerged as a novel mucoadhesive drug delivery system that offers an alternative approach to conventional opioid therapy. Buprenorphine is a partial μ-opioid receptor agonist and κ-opioid receptor antagonist with high receptor affinity, providing potent analgesia while exhibiting a ceiling effect on respiratory depression. The buccal film formulation adheres to the oral mucosa, enabling direct systemic absorption and avoidance of first-pass hepatic metabolism, thereby enhancing bioavailability and ensuring consistent plasma drug levels. This review discusses the pharmacological profile of buprenorphine, the principles of mucoadhesive buccal drug delivery, formulation strategies, and clinical efficacy of buprenorphine buccal films in chronic pain management. Additionally, safety, tolerability, patient compliance, and therapeutic advantages over traditional oral and transdermal opioid formulations are critically evaluated. Overall, buprenorphine buccal film represents a promising advancement in chronic pain therapy, combining effective analgesia with improved safety and patient-friendly drug delivery.

Keywords: Buprenorphine, opioid, buccal patch, mucoadhesion, swelling, pain management

Downloads

Download data is not yet available.

References

1. Urits I, Pham C, Swanson D, Berardino K, Bandi P, Amgalan A, Kaye RJ, Jung JW, Kaye AD, Paladini A, Varrassi G. The utilization of buprenorphine in chronic pain. Best Practice & Research Clinical Anaesthesiology. 2020 Sep 1;34(3):355-68.
2. Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, Varrassi G, Urits I, Viswanath O, Kaye AM, Kaye AD. Buprenorphine and its formulations: a comprehensive review. Health psychology research. 2022 Aug 20;10(3):37517.
3. Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018 Aug;78(12):1211-28.
4. Urits I, Viswanath O, Petro J, Yazdi C. Building a bridge between primary and perioperative care: addressing the challenges of perioperative buprenorphine maintenance and postdischarge therapy. Ochsner Journal. 2018 Dec 21;18(4):305-7.
5. Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS drugs. 2019 Jun 5;33(6):567-80.
6. Gress K, Charipova K, Jung JW, Kaye AD, Paladini A, Varrassi G, Viswanath O, Urits I. A comprehensive review of partial opioid agonists for the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology. 2020 Sep 1;34(3):449-61.
7. Webster L, Gudin J, Raffa RB, Kuchera J, Rauck R, Fudin J, Adler J, Mallick-Searle T. Understanding buprenorphine for use in chronic pain: expert opinion. Pain Medicine. 2020 Apr 1;21(4):714-23.
8. Kenney SR, Anderson BJ, Bailey GL, Stein MD. Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management. Journal of substance abuse treatment. 2018 Nov 1;94:55-9.
9. Schmidt‐Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews. 2015(3).
10. Jonan AB, Kaye AD, Urman RD. Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures. Pain physician. 2018;21(1):E1.
11. Hale M, Garofoli M, Raffa RB. Benefit-risk analysis of buprenorphine for pain management. Journal of Pain research. 2021 May 24:1359-69.
12. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain physician. 2008;11(2S):S133.
13. Pergolizzi Jr JV, Raffa RB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. Journal of Pain Research. 2019 Dec 13:3299-317.
14. Aiyer R, Gulati A, Gungor S, Bhatia A, Mehta N. Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies. Anesthesia & Analgesia. 2018 Aug 1;127(2):529-38.
15. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: resultsof a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clinical therapeutics. 2004 Nov 1;26(11):1808-20.
16. Mitra F, Chowdhury S, Shelley M, Williams G. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Pain Medicine. 2013 Jan 1;14(1):75-83.
17. Pergolizzi Jr JV, Magnusson P, LeQuang JA, Breve F, Mitchell K, Chopra M, Varrassi G. Transdermal buprenorphine for acute pain in the clinical setting: a narrative review. Journal of pain research. 2021 Mar 31:871-9.
18. Londhe S, Patwardhan M, Shah R, Oak M. Efficacy and safety of buprenorphine transdermal patch for immediate postoperative analgesia after total knee arthroplasty surgery. The Journal of Arthroplasty. 2020 Jun 1;35(6):S178-81.